Edition:
India

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

25.57USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$25.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
151,751
52-wk High
$33.18
52-wk Low
$11.45

Latest Key Developments (Source: Significant Developments)

Apellis Pharmaceuticals Announces Pricing Of Offering Of Convertible Senior Notes
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF CONVERTIBLE SENIOR NOTES.APELLIS PHARMACEUTICALS INC - PRICING OF ITS OFFERING OF $220.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 3.500% CONVERTIBLE SENIOR NOTES DUE 2026.APELLIS PHARMACEUTICALS INC - APELLIS ESTIMATES THAT NET PROCEEDS FROM SALE OF NOTES WILL BE APPROXIMATELY $212.9 MILLION.APELLIS PHARMACEUTICALS INC - OFFERING IS EXPECTED TO CLOSE ON SEPTEMBER 16.  Full Article

Apellis Pharmaceuticals Announces Proposed Private Offering Of $200 Mln Of Convertible Senior Notes
Thursday, 12 Sep 2019 

Sept 11 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES.APELLIS PHARMACEUTICALS INC - INTENDS TO OFFER 200 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2026.  Full Article

Apellis Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Thursday, 7 Mar 2019 

March 6 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.APELLIS PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Apellis Pharmaceuticals' APL-2 Receives Fast Track Designation From The FDA
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.APELLIS PHARMACEUTICALS - NEW FAST TRACK DESIGNATION FOR APL-2 FOR ALL PATIENTS WITH PNH, SUPERSEDES PRIOR FAST TRACK DESIGNATION FROM ON DEC 15, 2016.  Full Article

Apellis Pharmaceuticals' Apl-2 Receives Orphan Drug Designation From FDA
Friday, 21 Dec 2018 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES ORPHAN DRUG DESIGNATION FROM THE FDA FOR THE TREATMENT OF C3 GLOMERULOPATHY.APELLIS PHARMACEUTICALS INC - ITS C3 COMPLEMENT INHIBITOR, APL-2, HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY FDA.  Full Article

Apellis Pharmaceuticals Provides Update On Its Phase 3 Program For Patients With Geographic Atrophy
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON ITS PHASE 3 PROGRAM FOR PATIENTS WITH GEOGRAPHIC ATROPHY.APELLIS PHARMACEUTICALS - PHASE 3 GEOGRAPHIC ATROPHY PROGRAM ENROLLMENT TIMELINE CURRENTLY UNCHANGED.APELLIS PHARMACEUTICALS INC - PROGRAM ENROLLMENT IS EXPECTED TO RESTART IN Q2 2019 AND ENROLLMENT COMPLETION IS EXPECTED IN Q1 2020.APELLIS PHARMACEUTICALS - TO RESUME PHASE 3 GA PROGRAM CO INTRODUCED IMPROVEMENTS TO MANUFACTURING PROCESS TO ELIMINATE IMPURITIES & POTENTIAL CONTAMINANTS.  Full Article

Apellis Pharmaceuticals Reports Q2 Loss Per Share Of $0.61
Wednesday, 1 Aug 2018 

July 31 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.61.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM CONSISTING OF 2 TRIALS OF APL-2 IN GEOGRAPHIC ATROPHY REMAINS ON TRACK TO BEGIN IN H2 2018.APELLIS PHARMACEUTICALS INC - AS OF JUNE 30, 2018, APELLIS HAD $253.8 MILLION IN CASH & CASH EQUIVALENTS VERSUS $152.9 MILLION AS OF MARCH 31, 2018.  Full Article

Apellis Pharma's APL-2 Receives Fast Track Designation From FDA
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH GEOGRAPHIC ATROPHY.APELLIS PHARMACEUTICALS - APELLIS PLANS TO INITIATE A PHASE 3 TRIAL FOR PATIENTS WITH GA LATER IN 2018.  Full Article

Apellis Pharma Provides Update On Two Phase Ib Trials For Patients With PNH
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON TWO PHASE IB TRIALS FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).APELLIS - SEVERELY ANEMIC PATIENTS WITH PNH ON TREATMENT WITH SOLIRIS CAN BECOME TRANSFUSION-FREE WHEN SWITCHED TO APL-2 MONOTHERAPY.APELLIS - TREATMENT-NAÏVE PATIENTS WITH PNH SHOW CLINICALLY MEANINGFUL IMPROVEMENTS FOR ALL HEMATOLOGICAL PARAMETERS WHEN TREATED WITH APL-2.APELLIS - SUBCUTANEOUS APL-2 HAS GENERALLY BEEN WELL-TOLERATED WITH CUMULATIVE SYSTEMIC EXPOSURE OF OVER 12 PATIENT YEARS OF TREATMENT ON APL-2.  Full Article

Apellis Pharmaceuticals Announces Pricing Of Offering Of Common Stock
Thursday, 19 Apr 2018 

April 18 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON STOCK.APELLIS PHARMACEUTICALS- PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $25.50 PER SHARE.  Full Article